C-reactive protein and atherothrombosis - Beyond a biomarker: An actual partaker of lesion formation

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 285, Issue 5 54-5, 2003, Pages

  Verma, Subodh ^a,b,d   Yeh, Edward T H ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF TEXAS   (United States)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN;

ANGIOGENESIS; ATHEROSCLEROSIS; BONE MARROW CELL; CELL ACTIVATION; DISEASE MARKER; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; INFLAMMATION; LIPID TRANSPORT; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

EID: 0142095224     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00170.2003     Document Type: Review

References (27)

1. Blake GJ and Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 89: 763-771, 2001.
2. Devaraj S, Xu DY, and Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107: 398-404, 2003.
3. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, and Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102: 1000-1006, 2000.
4. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, and Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593-600, 2003.
5. Libby P and Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 8: 1257-1262, 2002.
6. Libby P. Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
7. Palusinski RP, Vaisman D, Pasceri V, Yeh ETH, and Willerson JT. Synergy between CD14 and C-reactive protein in endothelial cell activation (Abstract). Circulation 106, Suppl II: 2634, 2002.
8. Pasceri V, Chang J, Willerson JT, and Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103: 2531-2534, 2001.
9. Pasceri V, Willerson JT, and Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165-2168, 2000.
10. Pradhan AD, Manson JE, Rifai N, Buring JE, and Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334, 2001.
11. Ridker PM, Rifai N, Rose L, Buring JE, and Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565, 2002.
12. Ridker PM, Stampfer MJ, and Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285: 2481-2485, 2001.
13. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107: 363-369, 2003.
14. Szmitko PE, Fedak PWM, Weisel RD, Stewart DJ, Kutryk MJB, and Verma S. Endothelial progenitor cells: new hope for a broken heart. Circulation 107: 3093-3100, 2003.
15. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, and Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106: 1439-1441, 2002.
16. Verma S and Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 105: 546-549, 2002.
17. Verma S, Buchanan M, and Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. In press.
18. Verma S, Kuliszewski MA, Mickle DAG, Weisel RD, Fedak PWM, Li SH, Stewart DJ, and Kutryk MJB. C-reactive protein attenuates endothelial progenitor cell survival and differentiation (Abstract). Can J Cardiol 18, Suppl B: 325, 2002.
19. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, and Mickle DAG. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105: 1890-1896, 2002.
20. Verma S, Li SH, Wang CH, Weisel RD, Badiwala MV, Li SH, Fedak PWM, Li RK, and Mickle DAG. Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. J Mol Cell Cardiol 35: 417-419, 2003.
21. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, and Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106: 913-919, 2002.
22. Verma S, Badiwala MV, Weisel RD, Li SH, Fedak PWM, Li RK, and Mickle DAG. C-reactive protein upregulates the NFκB signaling pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg. In press.
23. Wang CH, Li SH, Weisel RD, Fedak WM, Dumont AS, Szmitko P, Li RK, Mickle AG, and Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107: 1783-1790, 2003.
24. Yeh ET, Anderson HV, Pasceri V, and Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation 104: 974-975, 2001.
25. Yeh ET and Palusinski RP. C-reactive protein: the pawn has been promoted to queen. CurrAtheroscler Rep 5: 101-105, 2003.
26. Yeh ET and Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 107: 370-371, 2003.
27. Zwaka TP, Hombach V, and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103: 1194-1197, 2000.